Copyright
©The Author(s) 2024.
World J Methodol. Sep 20, 2024; 14(3): 91832
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.91832
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.91832
Medication | Total patients | Percentage (%) |
Metformin | 74 | 69.8 |
SGLT2 inhibitors | 55 | 51.9 |
Sulfonylureas | 27 | 25.5 |
Pioglitazone | 7 | 6.6 |
Meglitinides | 1 | 0.9 |
DPP4 inhibitors | 6 | 5.7 |
Insulin | 74 | 69.8 |
Anti-obesity medications | 1 | 0.9 |
- Citation: Alkhalifah M, Afsar H, Shams A, Blaibel D, Chandrabalan V, Pappachan JM. Semaglutide for the management of diabesity: The real-world experience. World J Methodol 2024; 14(3): 91832
- URL: https://www.wjgnet.com/2222-0682/full/v14/i3/91832.htm
- DOI: https://dx.doi.org/10.5662/wjm.v14.i3.91832